---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-140955"
form_type: "8-K"
ticker: "INGN"
cik: "0001294133"
company_name: "Inogen Inc"
filed_at: "2024-12-30T23:59:59+00:00"
generated_at: "2026-05-28T22:39:32.902720+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Inogen receives FDA 510(k) clearance for SIMEOX 200, triggering $13M milestone payment

## Summary
- FDA cleared SIMEOX 200 for airway clearance and bronchial drainage in patients with chronic lung diseases.
- Clearance triggers $13M cash earnout payment to Physio-Assist sellers under July 2023 purchase agreement.
- Device targets mucus hypersecretion in Bronchiectasis, COPD, Cystic Fibrosis, and Primary Ciliary Dyskinesia.
- Inogen plans limited U.S. launch in 2025 via existing HCP, B2B, and direct-to-patient channels.

## SEC filing metadata
- accession: 0000950170-24-140955
- form_type: 8-K
- ticker: INGN
- cik: 0001294133
- company_name: Inogen Inc
- filed_at: 2024-12-30T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1294133/000095017024140955/0000950170-24-140955-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1294133/000095017024140955/ingn-20241230.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-140955
- JSON: https://secwatch.observer/filing/0000950170-24-140955.json
- Plain text: https://secwatch.observer/filing/0000950170-24-140955.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.